Seattle Genetics Inc (SGEN)

52.85
1.10 2.00
NASDAQ : Health Care
Prev Close 51.79
Open 51.57
Day Low/High 51.41 / 52.95
52 Wk Low/High 26.02 / 50.67
Volume 1.23M
Avg Volume 1.19M
Exchange NASDAQ
Shares Outstanding 143.03M
Market Cap 7.56B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics To Present At Morgan Stanley Global Healthcare Conference

Seattle Genetics To Present At Morgan Stanley Global Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017 at 2:05 p.

Genmab And Seattle Genetics To Co-develop Tisotumab Vedotin For Solid Tumors

Genmab And Seattle Genetics To Co-develop Tisotumab Vedotin For Solid Tumors

Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Seattle Genetics, Inc.

Seattle Genetics Announces Purchase Of Bothell Manufacturing Facility From Bristol-Myers Squibb

Seattle Genetics Announces Purchase Of Bothell Manufacturing Facility From Bristol-Myers Squibb

Seattle Genetics, Inc. (Nasdaq: SGEN), a biotechnology company, today announced that it has signed definitive agreements to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in Bothell, Washington.

Seattle Genetics Reports Second Quarter 2017 Financial Results

Seattle Genetics Reports Second Quarter 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the second quarter ended June 30, 2017.

Health Canada Approves ADCETRIS® (Brentuximab Vedotin) For The Post-ASCT Consolidation Treatment Of Patients With Hodgkin Lymphoma At Increased Risk Of Relapse Or Progression

Health Canada Approves ADCETRIS® (Brentuximab Vedotin) For The Post-ASCT Consolidation Treatment Of Patients With Hodgkin Lymphoma At Increased Risk Of Relapse Or Progression

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that Health Canada has issued a non-conditional marketing authorization for use of ADCETRIS as post-autologous stem cell transplant (ASCT) consolidation treatment of...

Seattle Genetics Announces Clinical Collaboration To Expand The Therapeutic Evaluation Of SGN-LIV1A In Triple Negative Breast Cancer

Seattle Genetics Announces Clinical Collaboration To Expand The Therapeutic Evaluation Of SGN-LIV1A In Triple Negative Breast Cancer

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a clinical collaboration agreement with Genentech, a member of the Roche Group, for the evaluation of its investigational antibody-drug...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 27, 2017

Seattle Genetics To Host Conference Call And Webcast Discussion Of Second Quarter Financial Results On July 27, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter financial results on Thursday, July 27, 2017 after the close of financial markets.

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Valeant Higher on Paulson Stake Increase; ImmunoGen Pops; Seattle Genetics Perplexes: Biotech Movers

Seattle Genetics, FibroGen and Sangamo were among the biotech stock movers in premarket trading on June 26.

Http://www.seagen.com/

Takeda Pharmaceutical Company Limited ( TSE:4502) and Seattle Genetics, Inc.

Seattle Genetics Submits Supplemental Biologics License Application To FDA For ADCETRIS® (Brentuximab Vedotin) In Cutaneous T-Cell Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.

Biotech Movers: Clovis, Seattle Genetics, Rigel

Biotech Movers: Clovis, Seattle Genetics, Rigel

Clovis Oncology, Seattle Genetics and Rigel Pharmaceuticals were among the biotech stock movers in premarket trading on June 19.

Seattle Genetics Discontinues Phase 3 CASCADE Trial Of Vadastuximab Talirine (SGN-CD33A) In Frontline Acute Myeloid Leukemia

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid...

Seattle Genetics And Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Relapsed Hodgkin Lymphoma At The International Conference On Malignant Lymphoma

Seattle Genetics, Inc. (Nasdaq: SGEN) and Bristol-Myers Squibb Company (NYSE: BMY) today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin)...

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Huge profits could be on the doorstep for these hot breakout setups.

Seattle Genetics And Astellas Announce Updated Enfortumab Vedotin Phase 1 Data In Metastatic Urothelial Cancer At 2017 ASCO Annual Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas today highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral...

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

Here are Tuesday's top research calls, including downgrades for Cisco Systems and TherapeuticsMD, and new coverage of Costco and J.C. Penney.

Seattle Genetics To Present At Bank Of America Merrill Lynch 2017 Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16 at 9:20 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, AVD, BCC, BGSF, CDR, CTRE, DV, LUK, PHX, PRLB, RTIX, SFM, STAY, TRP, WAGE, ZAGG Downgrades: ABCO, ACIW, AMAG, CQP, HDNG, INT, NEWM, RGS, SGEN, SSP, TAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Immunomedics, Seattle Genetics Scrap License Deal

Immunomedics, Seattle Genetics Scrap License Deal

Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics.

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Biotech Movers: Immunomedics Shares Jump After License Pact with Seattle Genetics Is Terminated

Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.

Seattle Genetics Terminates License Agreement With Immunomedics For Sacituzumab Govitecan (IMMU-132)

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc.

Seattle Genetics Reports First Quarter 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today reported financial results for the first quarter ended March 31, 2017.

Seattle Genetics To Host Conference Call And Webcast Discussion Of First Quarter Financial Results On April 27, 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 27, 2017, after the close of financial markets.

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate And Novel Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted multiple data presentations that support the company's advancing antibody-drug conjugate (ADC) and immuno-oncology programs at...

TheStreet Quant Rating: D (Sell)